Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021723 · ClinicalTrials.gov registry record · Phase 2
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
A Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
NCT00021723: Clinical Trial Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT00021723 is a Phase 2 study that was terminated before completion, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 375 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (182% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021723, a Phase 2 study, was terminated before completion, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
Study Summary
A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.
Interventions
- BIOLOGICAL AN-1792 also known as AIP-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Why NCT00021723 stopped before completion
NCT00021723 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (182% higher).
The record links to 0 conditions, and to 1 intervention - of which AN-1792 also known as AIP-001 is the first listed.
NCT00021723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00021723 about?
NCT00021723 is a clinical study titled "Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease". A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.
What is the current status of trial NCT00021723?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2001-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00021723?
The interventions under investigation include: AN-1792 also known as AIP-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00021723?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00021723's enrollment target sits among peer trials
375 116th of 2000 higher than 1,883 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia